Phase 2 N=53 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Lymphoma
Primary: 3 Year Progression-Free Survival Rate — 30 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 Open-Label Study of OTO-201 for Treatment of AOMT
Acute Otitis Media · AOMT
Primary: Number of Ears With Otorrhea (Drainage From the Middle Ear) — 8 affected ears
Phase 2 N=19 Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Number of Participants With Drug-Related Serious Adverse Events (SAEs) — 0 Participants
Phase 2 N=2 Renal Allograft Tolerance Through Mixed Chimerism
End Stage Renal Disease
Primary: Successful Withdrawal of Immunosuppressive Therapy — 2 Participants
Phase 2 N=210 Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Absolute Change From Baseline in Mean Noninflammatory Lesion Count to Week 12 — -21.6; -20.3; -13.1 lesions
Phase 2 N=233 Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin
Pruritus
Primary: Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10 — 46; 44 Participants — p=0.5861
Phase 2 N=133 A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigator Radiologic Review — 2.9; 5.7…
Phase 2 N=99 A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Primary: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 — 8.14; -40.01; -30.14; -40.13 percent change — p=0.0000
Phase 2 N=22 Safety Study of RMJH-111b to Treat Essential Hypertension
Essential Hypertension
Primary: Safety and Tolerability of RMJH-111b Compared to Placebo Based on Treatment Emergent Adverse Events (TEAEs) — 5; 1; 0; 0 Participants
Phase 2 N=43 Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease
Cardiovascular Disease · Chronic Kidney Disease
Primary: Aortic Pulse Wave Velocity (PWV) — 9.90; 9.96; 7.62; 8.57 m/s — p=0.685
Phase 2 N=75 OTO-201 for the Treatment of Otitis Externa
Otitis Externa
Primary: Otoscopic Examination: Tympanic Membrane — 6; 8; 8 Participants
Phase 2 N=420 RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
Respiratory Syncytial Virus Infections
Primary: PRNT (Subtype A) GMT — 300.5; 278.9; 311.9; 373.3 Titer
Phase 2 N=376 Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
Ovarian Neoplasms
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in All Cohort A and…
Phase 2 N=39 Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
Idiopathic Pulmonary Fibrosis · Hypoxemia
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03 — 8; 7; 4; 11 Participants
Phase 2 N=24 HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
Primary: Tumor Radiographic Response as Assessed by the RANO Criteria — 0; 0; 7; 17 Participants